You are here
Naureen StarlingNew ESMO clinical practice guidelines on gastric cancer were published in 2016. Dr Starling takes the audience on a journey that addresses: the advances in chemotherapy treatments over the past 2 decades, the impact of targeted therapies, and the relatively new area of checkpoint inhibitors. She summarises many of the negative clinical trial results and highlights emerging areas of clinical research in advanced/metastatic gastric and gastroesophageal junction (GEJ) cancer.
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al.J Clin Oncol. 2016 Feb 16. [Epub ahead of print]
Giandomenico Roviello, Andrea Ravelli, Karol Polom, Roberto Petrioli, Luigi Marano, Daniele Marrelli, Franco Roviello, Daniele Generali
Cancer Letters, Volume 372, Issue 2, March 2016, Pages 187 - 191